Overview
Subscribe
VC Statistics
Back to VC Home
MedTRACK
MedTRACK Japan
Report Center

 
Venture Finance Statistics

Our Venture Finance Database, which includes many of the Life Science Venture Financing transactions over the last fifteen years, is updated on a daily basis. We rely on annual reports, regulatory filings, press releases, articles, websites and company contacts to source this information. Venture finance is subject to timing and we combine the most up-to-date information with the ability to gain a historical perspective by searching the database. We have summarized Venture Financing Rounds for your convenience and will continue to update them as our database expands.

Top 15 Investment Firms in 2007 based on Rounds of Financing
Firm NameRoundsCapital Amount
(USD Millions)
New Enterprise Associates (NEA)426000
Alta Partners332000
MPM Capital272500
Three Arch Partners261000
Domain Associates, L.L.C.252000
Atlas Venture242000
Oxford Bioscience Partners241000
Versant Venture Management LLC231000
Pittsburgh Life Sciences Greenhouse22--
Polaris Venture Partners213000
Frazier Healthcare Ventures201200
Novartis Venture Funds (subsidiary of Novartis International AG)20500
InterWest Partners LLC182000
OrbiMed Advisors, LLC186000
Johnson & Johnson Development Corporation (Venture arm of Johnson & Johnson)18--

Top 15 Investment Raised Companies during 2007
Company NameAmount Raised
(USD Millions)
XLHealth290
Lexicon Pharmaceuticals, Inc205
Xanodyne Pharmaceuticals, Inc. (formerly Xanodyne Pharmacal)195
EUSA Pharma Inc.175
Patheon Inc.150
CardioNet, Inc.110
Globus Medical, Inc.110
Solantic100
Zosano Pharma, Inc.90
Sientra, Inc85
Ception Therapeutics77
Inspire Pharmaceuticals Inc75
Cytokinetics Inc75
Bayhill Therapeutics, Inc.72.8
Gemin X Pharmaceuticals, Inc.72.6





 
 
Current Statistics
Total Transactions10997
Total Companies4516
Total Firms5641

800 James Ave.
Suite 201
Scranton, PA 18510

If you would like immediate response, you may contact directly.
Telephone:
570-504-1800
email: info@medtrack.com


 
The information contained herein is based on sources believed to be reliable but is neither all-inclusive nor guaranteed by Life Science Analytics ("LSA"). Opinions, if any, reflect the judgment of LSA at this time and are subject to change. LSA does not undertake to advise you of changes in their opinion or information. Most of the companies LSA follows are emerging growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in the reports included in LSA's Database may be unsuitable for investors depending on their specific investment objectives, financial situation and needs. No report included in the LSA Database is a recommendation that any particular investor should purchase or sell any particular security in any amount or at all, and is not a solicitation of any offer to purchase or sell from or to any particular investor. For additional information that may be available on the securities mentioned, please contact Life Science Analytics.